前B细胞克隆增强因子在炎症和急性肺损伤中的作用  

Role of pre-B cell colony-enhancing factor in inflammation and acute lung injury

作　　者：舒化青[1] 姚尚龙[1] 

机构地区：[1]华中科技大学附属协和医院麻醉科,武汉430022

出　　处：《国际麻醉学与复苏杂志》2009年第4期357-359,共3页International Journal of Anesthesiology and Resuscitation

基　　金：国家自然科学基金资助项目（30571787）

摘　　要：前B细胞克隆增强因子（pre-Bcellcolony—enhancing factor，PBEF）最初是从人类外周血淋巴细胞中分泌的细胞因子样分子，最近发现PBEF也是一种新的具有结合并激活胰岛素受体、模拟胰岛素作用的脂肪细胞因子。PBEF还具有其他多种生物学活性，如调控B细胞分化、延缓中性粒细胞凋亡、参与炎症和免疫应答，可能参与了多种疾病的发生，比如急性肺损伤（acute lung injury，ALI）、脓毒症、冠状动脉粥样硬化、早产、糖尿病、癌症等，在急性肺损伤中具有生物标志作用。目前PBEF在机体内的具体作用机制尚不十分清楚，但其发现可能为研究相关疾病的发病机制及诊断与治疗提供新的思路。Pre-B-cell colony-enhancing factor （PBEF） is considered originally as cytokine-like molecule secreted by lymphocyte from human peripheral blood. PBEF has been recently identified as a new adipocytokine exerting insulin-mimetic effects by binding to the insulin receptor. PBEF also presents a variety of other biological activations, such as inducing B- cell differentiation, inhibiting neutrophil apoptosis, affecting immune and inflammatory functions, accordingly involving in several diseases such as acute lung injury （ALI）, sepsis, atherosclerosis, pre-term labor, diabetes and cancer. It plays as a role of novel biomarker in ALL Although the molecular mechanisms in the pathogenesis of these diseases are unknown, the discovery of PBEF may provide new idea and tool for studying the mechanisms of some diseases and their diagnosis and treatment.

关 键 词：前B细胞克隆增强因子 炎症 急性肺损伤 

分 类 号：R563[医药卫生—呼吸系统]